Close Alert

Return to Campus Update

Coronavirus (COVID-19): The latest updates about USciences return to campus: The full plan for a phased return of employees and students:

USciences Announces Additions to its Board of Trustees

By Brian Kirschner

University of the Sciences has named three new members to its board of trustees. Board chairman Marvin Samson has announced that Carla Hendricks, Director of Tax Planning at NewsCorp/Dow Jones; Michael C. Hemsley, Esq., Deputy General Counsel at Trinity Health Corporation; and Michael J. Sofia, PhD, Chief Scientific Officer at Arbutus Biopharma, have joined the board. Responsibilities of the University’s board include, but are not limited to, approving the University’s strategic plans and ensuring their consistency with the institution’s mission and goals.

carla hendricksCarla Hendricks has spent her career as tax professional with U.S. and international responsibilities helping companies implement tax strategies and analyze complex situations. She has a successful and extensive track record of working with senior management while managing various tax and accounting related projects. Since January 2015, Hendricks has been serving at Dow Jones/News Corp as director of tax planning. Prior to that role, she was a senior director of tax planning and reporting at Tyco International, Inc. in Princeton, N.J., where she began in 2005, helping senior leadership to manage various national and international tax planning projects, developing global tax planning strategies, and managing cross functional teams. Hendricks joined Tyco after eight years with Unisys Corporation. Other stops on her career path include ARCO Chemical Company, Basell Polyolefins, and Ernst & Young. She graduated magna cum laude from La Salle University with a degree in accounting and completed her masters of taxation degree at Widener University. She has been a certified public account since 1985. Hendricks resides in Langhorne, Pa., with her husband and daughter.

MIchael HemsleyMichael C. Hemsley serves as deputy general counsel for Trinity Health, one of the largest health systems in the United States. Trinity consists of 20 Regional Health Ministries operating more than 56 hospitals as well as sub-acute healthcare facilities and businesses across the continuum of care in 21 states. Prior to its 2014 merger into Trinity, Hemsley served as executive vice president and general counsel for Catholic Health East ("CHE"), a similarly structured healthcare system operating in 11 states. For several years, he also served as CHE's corporate compliance officer, providing oversight and guidance to regional compliance officers and boards across its regional subsidiaries. Prior to joining CHE, Hemsley spent more than 20 years in private practice, last as a partner and chair of the health law department at Wolf, Block, LLP. Hemsley is a member of the American Health Lawyers Association, the Pennsylvania Bar Association, and the District of Columbia Bar Association. A certified healthcare compliance professional, Hemsley is a member of the Health Care Compliance Association, where he served as a board member and officer. A lecturer and author, he was a principal drafter of Corporate Responsibility and Corporate Compliance: A Resource for Health Care Boards of Directors and two subsequent Healthcare Board Educational Resource publications, each sponsored by the American Health Lawyers Association and the Office of Inspector General of the U.S. Department of Health and Human Services. Hemsley also has served as a member of the adjunct faculty of St. Joseph’s University, Philadelphia, Pa. He received his law degree (JD) from Villanova University School of Law, a master of arts in Legislative Affairs from The George Washington University, Washington, D.C., and a bachelor of science in international relations from St. Joseph’s University in Philadelphia, Pa. He is married with two grown children and resides in Drexel Hill, Pa.

Michael SophiaMichael J. Sofia, PhD, is the chief scientific officer at Arbutus Biopharma Corporation, a publicly-traded biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B infection. Arbutus was formed following the merger of OnCore Biopharma and Tekmira Pharmaceuticals Corporation. Dr. Sofia was one of OnCore Biopharma’s co-founders and has served as its chief scientific officer and head of research and development since July 2014. Previously, he was president and a member of its board of directors from May 2012 to August 2014. Since April 2012, Dr. Sofia has been a professor at the Baruch S. Blumberg Institute and since March 2013, he has been an adjunct professor at the Drexel University School of Medicine. From January 2012 to December 2012, Dr. Sofia was the senior vice-president, chemistry, site head and then senior advisor at Gilead Sciences, Inc. Prior to that, Dr. Sofia was the senior vice-president, chemistry at Pharmasset, Inc., from August 2005 to January 2012. From 1999 to 2005, Dr. Sofia served as a group director, new leads chemistry, at Bristol-Myers Squibb. From 1993 to 1999, Dr. Sofia established and directed the research programs at Transcell Technologies, first as director of chemistry and then as vice-president of research. Dr. Sofia has won a number of awards, among them the Economist’s 2015 Innovation Award in the bioscience category for developing a rapid cure for hepatitis C virus infection (HCV) and in September 2016 was named as one of six recipients of The Lasker Awards, which are among the most respected prizes in medicine, by the Albert and Mary Lasker Foundation. Dr. Sofia received his BA degree from Cornell University, his PhD degree from the University of Illinois at Urbana-Champaign, and was an NIH postdoctoral fellow at Columbia University. He resides in Buckingham, Pa.

University of the Sciences has prepared students to be leaders and practitioners in the healthcare and science fields for nearly 200 years. Key to its distinctive education is a tradition of hands-on research and experiential learning that is evident in every graduate who has walked its campus. Since its founding in 1821 as Philadelphia College of Pharmacy, the first college of pharmacy in North America, USciences has grown to more than 30 degree-granting programs from bachelor’s through doctoral degrees in the health sciences, bench sciences, and healthcare business and policy fields. Discover how USciences students are proven everywhere they go at

Categories: News, Announcement, Board of TrusteesUSciences